**REMARKS** 

Applicants submit the preceding amendment in order to reduce the number of issues on

appeal. Support for human LXRa derives from at least page 14, line 25 of the specification.

Thus, no new matter is raised by this amendment.

The insect ecdysone receptor disclosed in Hogness et al. is clearly distinct from human

LXRa, if only on the basis of its origin. Thus, entry of the amendments will obviate this

rejection.

Should the examiner have any questions regarding this amendment, a telephone call to

the undersigned is invited. Please date stamp and return the enclosed postcard to evidence receipt

of this document.

Respectfully submitted,

Steven 1. Highlander

Reg. No. 37,642

Attorney for Appellants

Fulbright & Jaworski 600 Congress Ave., Suite 2400 Austin TX 78701 512-536-3184

Date:

November 17, 2003